Develops an AI-driven platform that uses cell simulations and advanced aging clocks to discover gene-based interventions that reverse epigenetic aging without inducing stem cell identity. This technology enables the screening of over a billion small molecule combinations to identify potential therapeutics for age-related diseases, addressing the growing healthcare challenge posed by chronic conditions linked to aging.
Funding
$17.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic diseases linked to aging pose a significant healthcare challenge, but current methods for discovering interventions to reverse epigenetic aging often induce stem cell identity, raising safety concerns. Screening potential therapeutics for age-related diseases is also limited by the vast number of small molecule combinations.
Solution
Shift Bioscience has developed an AI-driven platform that leverages cell simulations and advanced aging clocks to identify gene-based interventions capable of reversing epigenetic aging without inducing stem cell identity. The platform screens over a billion small molecule combinations _in silico_ and up to 2000 molecules _in vitro_ to pinpoint therapeutics with a cell-rejuvenation mechanism of action. By integrating single-cell transcriptomic aging clocks within AI-powered virtual cells, Shift accelerates the discovery process, reducing years of experimentation to weeks. This approach enables the identification of single genes that rejuvenate multiple cell types more safely, along with small molecule targets and connections to fibrosis.
Target Audience
Shift Bioscience targets pharmaceutical companies and research institutions focused on developing therapeutics for age-related diseases.
Features
- AI-powered virtual cell platform for simulating cell behavior and identifying rejuvenation factors
- Proprietary datasets uncovering the biology of cell aging and rejuvenation
- Advanced cell aging clocks (AC3) for precise measurement of epigenetic age
- Ability to screen over a billion small molecule combinations _in silico_
- Identification of novel gene-based interventions that reverse epigenetic age without inducing stem cell identity
- Pipeline of cell rejuvenation genes, siRNA, and small molecule inhibitors of pro-aging genes
- Identification of genes individually sufficient to rejuvenate epigenetic age across multiple cell types